About Immunoglobulin heavy constant alpha 1
Immunoglobulin heavy constant alpha 1 (IGHA1) is a protein
from Homo sapiens identified by UniProt accession
P01876, 398 residues long.
MolForge cross-references it against 0 known binders and
437 disease associations.
Target properties
| Protein name | Immunoglobulin heavy constant alpha 1 |
| UniProt accession | P01876 |
| Gene | IGHA1 |
| Organism | Homo sapiens |
| Length | 398 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | LOW |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (437)
Diseases linked to this target (Open Targets).
- IGA glomerulonephritis · score 0.12
- chronic kidney disease · score 0.10
- Rheumatoid arthritis · score 0.09
- hepatocellular carcinoma · score 0.09
- ulcerative colitis · score 0.08
- inflammatory bowel disease · score 0.08
- isolated agammaglobulinemia · score 0.08
- sebaceous of Jadassohn nevus · score 0.07
- squamous cell carcinoma · score 0.07
- immunodeficiency 35 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01876-F1 | alphafold | PREDICTED | 81.85 | — |
Amino-acid sequence (398 residues)
ASPTSPKVFP LSLCSTQPDG NVVIACLVQG FFPQEPLSVT WSESGQGVTA RNFPPSQDAS GDLYTTSSQL TLPATQCLAG KSVTCHVKHY TNPSQDVTVP CPVPSTPPTP SPSTPPTPSP SCCHPRLSLH RPALEDLLLG SEANLTCTLT GLRDASGVTF TWTPSSGKSA VQGPPERDLC GCYSVSSVLP GCAEPWNHGK TFTCTAAYPE SKTPLTATLS KSGNTFRPEV HLLPPPSEEL ALNELVTLTC LARGFSPKDV LVRWLQGSQE LPREKYLTWA SRQEPSQGTT TFAVTSILRV AAEDWKKGDT FSCMVGHEAL PLAFTQKTID RLADWQMPPP YVVLDLPQET LEEETPGANL WPTTITFLTL FLLSLFYSTA LTVTSVRGPS GNREGPQY
Explore Immunoglobulin heavy constant alpha 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets